✦ LIBER ✦

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

✍ Scribed by Benjamin Terrier; Zahir Amoura; Philippe Ravaud; Eric Hachulla; Romain Jouenne; Bernard Combe; Christine Bonnet; Patrice Cacoub; Alain Cantagrel; Michel De Bandt; Olivier Fain; Bruno Fautrel; Philippe Gaudin; Bertrand Godeau; Jean-Robert Harlé; Arnaud Hot; Jean-Emmanuel Kahn; Olivier Lambotte; Claire Larroche; Jean Léone; Olivier Meyer; Béatrice Pallot-Prades; Edouard Pertuiset; Pierre Quartier; Thierry Schaerverbeke; Jean Sibilia; Alexandre Somogyi; Martin Soubrier; Eric Vignon; Brigitte Bader-Meunier; Xavier Mariette; Jacques-Eric Gottenberg

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 157 KB
Volume: 62
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.27541

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of rituximab in nonv

Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry

✍ B. Terrier; D. Launay; G. Kaplanski; A. Hot; C. Larroche; P. Cathébras; B. Combe 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 102 KB 👁 1 views

Rituximab therapy for systemic vasculiti

Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the Autoimmunity and Rituximab Registry

✍ X. Puéchal; J. E. Gottenberg; J. M. Berthelot; L. Gossec; O. Meyer; J. Morel; D. 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 98 KB 👁 2 views

Efficacy and safety of rituximab in mode

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

✍ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 1 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p

Familial aggregation of systemic lupus e

Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort

✍ Donato Alarcón-Segovia; Marta E. Alarcón-Riquelme; Mario H. Cardiel; Francisco C 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Features associated with, and the impact

Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort

✍ Durán, Sergio ;Apte, Mandar ;Alarcón, Graciela S. ;Marion, Miranda C. ;Edberg, J 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Evaluation of the safety of rituximab in

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

✍ Maria W. Greenwald; William J. Shergy; Jeffrey L. Kaine; Marianne T. Sweetser; K 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views